人民财讯11月13日电，仁和药业（000650）11月13日公告，公司控股股东仁和(集团)发展有限公司因自 身发展需要，拟通过集中竞价或大宗交易的方式，减持公司股份不超过300万股，减持比例不超过公司 总股本的0.21%。 ...

仁和药业公告，截至公告披露日，控股股东仁和(集团)发展有限公司持有公司3.25亿股，占23.2367%； 因自身发展需要，拟自本公告披露之日起15个交易日后的3个月内，通过集中竞价或大宗交易方式减持 不超过300万股，减持比例不超过0.2143%；若减持期间公司发生送红股、转增股本、增发新股或配股 等事项，减持数量将相应调整，但减持股份占公司总股本的比例保持不变。 ...

Group 1 - The stock price of Renhe Pharmaceutical (000650) closed at 6.26 yuan on November 6, 2025, with no change in price, a turnover rate of 0.98%, a trading volume of 130,100 shares, and a transaction amount of 81.26 million yuan [1] - The company's classic formula, Er Dong Tang granules, did not participate in this year's medical insurance negotiations, as confirmed by the company secretary [2] - On November 6, there was a net outflow of 4.07 million yuan from main funds, indicating a cautious attitude from major investors [2] Group 2 - On the same day, there was a net inflow of 1.18 million yuan from speculative funds and a net inflow of 2.89 million yuan from retail investors [2]

Group 1 - The company, Renhe Pharmaceutical, stated on November 4 that it is currently not disclosing the number of shareholders on the interactive platform [2]

Core Insights - The "Green Leaf Guardian Plan" is a public welfare project initiated by the women's health brand, Yinhujie, under Renhe Pharmaceutical, focusing on improving health and development for women in remote areas [2][3] Group 1: Project Overview - The project aims to provide support through material donations and entrepreneurial empowerment, specifically targeting women's health and development in the Inner Mongolia region [1] - Over the past three years, the plan has donated nearly 4 million yuan in cash and materials, covering 4 provinces and 9 regions, and has established 5 women's health centers benefiting tens of thousands of women [2] Group 2: Activities and Collaborations - The initiative includes customized health gift packages and sanitary care products for local women, along with training courses in non-material cultural heritage crafts and e-commerce operations in collaboration with local women's federations [2] - The involvement of local intangible cultural heritage inheritors as brand ambassadors signifies a shift from health care to cultural transmission and economic empowerment for women [2] Group 3: Brand Commitment - Yinhujie has been dedicated to women's health for 26 years, expanding its product range from single care items to a comprehensive matrix including washes, medicines, and daily chemicals, with its women's care liquid being the top-selling category in China [3] - The brand's new strategy for 2025 emphasizes achieving a balance in women's health and life, with the "Green Leaf Guardian Plan" serving as a public welfare extension of this philosophy [3] Group 4: Future Directions - The recent activities in Hulunbuir represent an expansion of the "Green Leaf Guardian Plan," showcasing the brand's commitment to corporate social responsibility and support for women's development in China [4] - Yinhujie plans to continue its efforts in promoting women's health and development, aiming to extend its support to more areas in need [4]

Core Insights - Renhe Pharmaceutical reported a revenue of 2.833 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.07% [1] - The net profit for the same period was 379 million yuan, down 8.79% year-on-year, while the net profit excluding non-recurring items was 277 million yuan, a decline of 8.59% [1] - In the third quarter, the company achieved a revenue of 858 million yuan, representing a year-on-year increase of 9.16%, with net profit rising to 88.71 million yuan, up 13% [1] - The net profit excluding non-recurring items in the third quarter was 70.15 million yuan, showing a significant increase of 37.16% year-on-year [1] Financial Performance - For the first three quarters, the company's sales expenses amounted to 263 million yuan, a reduction of 26.79% compared to 360 million yuan in the previous year, primarily due to decreases in salary and advertising expenses [1]

Core Viewpoint - Renhe Pharmaceutical, established in December 1996, is a well-known pharmaceutical company with a strong product line and brand presence in the traditional Chinese medicine and health-related products sector [1] Group 1: Business Overview - The company primarily engages in the production and sale of traditional and Western medicines, raw materials, and health-related products, covering various dosage forms including solid and liquid preparations [1] - As of Q3 2025, Renhe Pharmaceutical reported a revenue of 2.833 billion yuan, ranking 21st out of 69 in the industry, with the industry leader Baiyunshan achieving 61.606 billion yuan [2] - The revenue composition includes 1.388 billion yuan from pharmaceuticals (70.25%), 549 million yuan from health-related products (27.79%), and 38.573 million yuan from other business products (1.95%) [2] Group 2: Financial Performance - The net profit for Q3 2025 was 469 million yuan, ranking 18th in the industry, with the top performer Yunnan Baiyao reporting 4.789 billion yuan [2] - The company's asset-liability ratio stood at 13.08% in Q3 2025, an increase from 10.32% in the previous year, which is significantly lower than the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 36.43%, down from 37.65% year-on-year, and also below the industry average of 52.44% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.42% to 97,700, while the average number of circulating A-shares held per shareholder increased by 6.86% to 13,600 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with 13.4878 million shares, an increase of 2.0013 million shares from the previous period [5]

Core Insights - Renhe Pharmaceutical reported a revenue of 858,360,283.90 yuan for Q3 2025, representing a year-on-year growth of 9.16% [1] - The net profit attributable to shareholders of the listed company was 88,708,927.17 yuan, showing a year-on-year increase of 13.00% [1]

Core Viewpoint - Renhe Pharmaceutical reported a revenue of 858 million yuan for Q3 2025, marking a year-on-year increase of 9.16%, with a net profit attributable to shareholders of 88.71 million yuan, up 13% [2] Financial Performance - For the first three quarters, the company achieved a revenue of 2.833 billion yuan, reflecting a year-on-year decline of 10.07% [2] - The net profit attributable to shareholders for the same period was 379 million yuan, down 8.79% year-on-year [2] - Basic earnings per share for Q3 2025 were 0.0634 yuan, while for the first three quarters, it was 0.2708 yuan [2]

证券代码：000650 证券简称：仁和药业 公告编号：2025-041 仁和药业股份有限公司 第十届董事会第四次会议决议公告 本公司及全体董事会成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 仁和药业股份有限公司（以下简称"公司"）第十届董事会第四次会议通知 于 2025 年 10 月 27 日以直接送达、电子邮件等方式发出，会议于 2025 年 10 月 30 日以现场与通讯结合方式在南昌元创国际 18 层公司会议室召开。会议应到董 事 9 人，实到董事 9 人。董事长杨潇先生主持本次会议，公司高管列席会议，会 议符合《中华人民共和国公司法》和《公司章程》的有关规定。经与会董事认真 审议，会议审议通过了如下议案。 二、董事会会议审议情况 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司 章程》等有关规定，因公司发展和管理工作需要，经公司总经理提名，董事会提 名委员会资格审查，董事会同意聘任罗晚秋女士、李欣女士（简历附后）为公司 副总经理，任期自董事会审议通过之日 ...